129 related articles for article (PubMed ID: 7722303)
1. Constitutive endocytosis and degradation of CD22 by human B cells.
Shan D; Press OW
J Immunol; 1995 May; 154(9):4466-75. PubMed ID: 7722303
[TBL] [Abstract][Full Text] [Related]
2. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
[TBL] [Abstract][Full Text] [Related]
3. B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking.
Chaouchi N; Vazquez A; Galanaud P; Leprince C
J Immunol; 1995 Apr; 154(7):3096-104. PubMed ID: 7534787
[TBL] [Abstract][Full Text] [Related]
4. Intracellular CD22 rapidly moves to the cell surface in a tyrosine kinase-dependent manner following antigen receptor stimulation.
Sherbina NV; Linsley PS; Myrdal S; Grosmaire LS; Ledbetter JA; Schieven GL
J Immunol; 1996 Nov; 157(10):4390-8. PubMed ID: 8906814
[TBL] [Abstract][Full Text] [Related]
5. CD22 as a target of passive immunotherapy.
Cesano A; Gayko U
Semin Oncol; 2003 Apr; 30(2):253-7. PubMed ID: 12720147
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of the B cell-restricted molecule CD22 on neonatal B lymphocytes depending upon antigen stimulation.
Viemann D; Schlenke P; Hammers HJ; Kirchner H; Kruse A
Eur J Immunol; 2000 Feb; 30(2):550-9. PubMed ID: 10671211
[TBL] [Abstract][Full Text] [Related]
7. B cell antigen receptor-evoked calcium influx is enhanced in CD22-deficient B cell lines.
Nadler MJ; McLean PA; Neel BG; Wortis HH
J Immunol; 1997 Nov; 159(9):4233-43. PubMed ID: 9379018
[TBL] [Abstract][Full Text] [Related]
8. Phosphotyrosine-dependent association between CD22 and protein tyrosine phosphatase 1C.
Campbell MA; Klinman NR
Eur J Immunol; 1995 Jun; 25(6):1573-9. PubMed ID: 7542197
[TBL] [Abstract][Full Text] [Related]
9. Association of CD22 with the B cell antigen receptor.
Peaker CJ; Neuberger MS
Eur J Immunol; 1993 Jun; 23(6):1358-63. PubMed ID: 7684686
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the expression and gene promoter of CD22 in murine B cells.
Andersson KB; Draves KE; Magaletti DM; Fujioka S; Holmes KL; Law CL; Clark EA
Eur J Immunol; 1996 Dec; 26(12):3170-8. PubMed ID: 8977319
[TBL] [Abstract][Full Text] [Related]
11. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus.
Lajaunias F; Ida A; Kikuchi S; Fossati-Jimack L; Martinez-Soria E; Moll T; Law CL; Izui S
Arthritis Rheum; 2003 Jun; 48(6):1612-21. PubMed ID: 12794829
[TBL] [Abstract][Full Text] [Related]
12. Membrane CD22 defines circulating myeloma-related cells as mature or later B cells.
Perfetti V; Vignarelli MC; Bellotti V; Glennie MJ; Zorzoli I; Ubbiali P; Obici L; Massa M; Ippoliti G; Ascari E; Merlini G
Lab Invest; 1997 Oct; 77(4):333-44. PubMed ID: 9354768
[TBL] [Abstract][Full Text] [Related]
13. Human hematopoietic cell lines: a model system for study of minimal residual disease detection technique in acute leukemia.
Koníková E; Kusenda J; Babusíková O; Glasová M
Neoplasma; 1995; 42(5):227-34. PubMed ID: 8552200
[TBL] [Abstract][Full Text] [Related]
14. Detection of intracellular lymphoid differentiation antigens by flow cytometry in acute lymphoblastic leukemia.
Sartor M; Bradstock K
Cytometry; 1994 Sep; 18(3):119-22. PubMed ID: 7813331
[TBL] [Abstract][Full Text] [Related]
15. SLP-76 is recruited to CD22 and dephosphorylated by SHP-1, thereby regulating B cell receptor-induced c-Jun N-terminal kinase activation.
Mizuno K; Tagawa Y; Watanabe N; Ogimoto M; Yakura H
Eur J Immunol; 2005 Feb; 35(2):644-54. PubMed ID: 15668918
[TBL] [Abstract][Full Text] [Related]
16. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
DiJoseph JF; Goad ME; Dougher MM; Boghaert ER; Kunz A; Hamann PR; Damle NK
Clin Cancer Res; 2004 Dec; 10(24):8620-9. PubMed ID: 15623646
[TBL] [Abstract][Full Text] [Related]
17. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor.
Sato S; Tuscano JM; Inaoki M; Tedder TF
Semin Immunol; 1998 Aug; 10(4):287-97. PubMed ID: 9695185
[TBL] [Abstract][Full Text] [Related]
18. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
19. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Press OW; Farr AG; Borroz KI; Anderson SK; Martin PJ
Cancer Res; 1989 Sep; 49(17):4906-12. PubMed ID: 2667754
[TBL] [Abstract][Full Text] [Related]
20. CD22 attenuates calcium signaling by potentiating plasma membrane calcium-ATPase activity.
Chen J; McLean PA; Neel BG; Okunade G; Shull GE; Wortis HH
Nat Immunol; 2004 Jun; 5(6):651-7. PubMed ID: 15133509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
